The present disclosure relates generally to the field of medical devices and methods, and more specifically to shock wave catheter devices for treating calcified lesions in body lumens, such as calcified lesions and occlusions in vasculature and kidney stones in the urinary system.
A wide variety of catheters have been developed for treating calcified lesions, such as calcified lesions in vasculature associated with arterial disease. For example, treatment systems for percutaneous coronary angioplasty or peripheral angioplasty use angioplasty balloons to dilate a calcified lesion and restore normal blood flow in a vessel. In these types of procedures, a catheter carrying a balloon is advanced into the vasculature along a guide wire until the balloon is aligned with calcified plaques. The balloon is then pressurized (normally to greater than 10 atm), causing the balloon to expand in a vessel to push calcified plaques back into the vessel wall and dilate occluded regions of vasculature.
More recently, the technique and treatment of intravascular lithotripsy (IVL) has been developed, which is an interventional procedure to modify calcified plaque in diseased arteries. The mechanism of plaque modification is through use of a catheter having one or more acoustic shock wave generating sources located within a liquid that can generate acoustic shock waves that modify the calcified plaque. IVL devices vary in design with respect to the energy source used to generate the acoustic shock waves, with two exemplary energy sources being electrohydraulic generation and laser generation.
For electrohydraulic generation of acoustic shock waves, a conductive solution (e.g., saline) may be contained within an enclosure that surrounds electrodes or can be flushed through a tube that surrounds the electrodes. The calcified plaque modification is achieved by creating acoustic shock waves within the catheter by an electrical discharge across the electrodes. This discharge creates one or more rapidly expanding vapor bubbles that generate the acoustic shock waves. These shock waves propagate radially outward and modify calcified plaque within the blood vessels. For laser generation of acoustic shock waves, a laser pulse is transmitted into and absorbed by a fluid within the catheter. This absorption process rapidly heats and vaporizes the fluid, thereby generating the rapidly expanding vapor bubble, as well as the acoustic shock waves that propagate outward and modify the calcified plaque. The acoustic shock wave intensity is higher if a fluid is chosen that exhibits strong absorption at the laser wavelength that is employed. These examples of IVL devices are not intended to be a comprehensive list of potential energy sources to create IVL shock waves.
The IVL process may be considered different from standard atherectomy procedures in that it cracks calcium but does not liberate the cracked calcium from the tissue. Hence, generally speaking, IVL should not require aspiration nor embolic protection. Further, due to the compliance of a normal blood vessel and non-calcified plaque, the shock waves produced by IVL do not modify the normal vessel or non-calcified plaque.
More specifically, catheters to deliver IVL therapy have been developed that include pairs of electrodes for electrohydraulically generating shock waves inside an angioplasty balloon. Shock wave devices can be particularly effective for treating calcified plaque lesions because the acoustic pressure from the shock waves can crack and disrupt lesions near the angioplasty balloon without harming the surrounding tissue. In these devices, the catheter is advanced over a guidewire through a patient's vasculature until it is positioned proximal to and/or aligned with a calcified plaque lesion in a body lumen. The balloon is then inflated with conductive fluid (using a relatively low pressure of 2-4 atm) so that the balloon expands to contact the lesion, but is not an inflation pressure that substantively displaces the lesion. Voltage pulses can then be applied across the electrodes of the electrode pairs to produce acoustic shock waves that propagate through the walls of the angioplasty balloon and into the lesions. Once the lesions have been cracked by the acoustic shock waves, the balloon can be expanded further to increase the cross-sectional area of the lumen and improve blood flow through the lumen. Alternative devices to deliver IVL therapy can be within a closed volume other than an angioplasty balloon, such as a cap, balloons of variable compliancy, or other enclosure.
Efforts have been made to improve the delivery of shock waves in these devices. For instance, forward-biased designs, such as the designs found in U.S. Pat. No. 10,966,737 and U.S. Publication No. 2019/0388110, both of which are incorporated herein by reference, direct shock waves in a generally forward direction (e.g., distally from the distal end of a catheter) to break up tighter and harder-to-cross occlusions in vasculature. Other catheter devices have been designed to include arrays of low-profile electrode assemblies that reduce the crossing profile of the catheter and allow the catheter to more easily navigate calcified vessels to deliver shock waves in more severely occluded regions of vasculature. For instance, U.S. Pat. Nos. 8,888,788, and 10,709,462 and U.S. Publication No. 2021/0085347, each of which is incorporated herein by reference, provide examples of low-profile electrode assemblies. Such forward-biased and low-profile designs are particularly useful when an artery is totally or partially occluded, for example, with thrombus, plaque, fibrous plaque, and/or calcium deposits. When treating such conditions, a physician must first cross the occlusion (e.g., pass through the occluded area), and then feed the angioplasty balloon and/or other tools down the artery to the blockage to perform the desired procedure. In some instances, however, such as the case of a chronic total occlusion (“CTO”), the occlusion may be so tight and solid that it is difficult to cross the treatment device into the true lumen of the distal vessel. Some physicians may implement atherectomy procedures (e.g., laser-based, mechanically cutting or shaving, mechanically rotating devices, etc.) to form a channel in a CTO in combination with an angioplasty balloon treatment, but many atherectomy devices and systems carry a higher risk of vessel perforation or vessel dissection as compared with a basic angioplasty balloon catheters.
Despite these advances, currently available shock wave catheters can encounter challenges treating CTOs. First, the navigability of the catheter in a CTO is limited by the crossing profile of the device. While certain low-profile designs improve the overall navigability of the device, even further crossing profile reductions can be necessary to navigate severely occluded vessels. Second, when navigating severely occluded vessels, the direction that the shock waves travel can dictate the ability to advance the catheter farther. Thus, it may be desirable to implement a forward-biased design in order to soften, weaken, or break up occlusions in vasculature such that the catheter can be incrementally advanced farther within the occlusion. Accordingly, there is an unmet need for low-profile catheter designs capable of producing forward-biased acoustic shock waves. Similar devices are needed for treating occlusions formed in other parts of the body, for example, kidney stones in the urinary system.
The above objectives are realized in a catheter that includes an electrode assembly with a cylindrical conductive sheath comprising one or more slots that provide a recessed location for the placement of insulated wires. The insulated wires can include a non-insulated distal end that forms a first electrode, while the conductive sheath forms the second electrode of an electrode pair. When voltage is supplied to the insulated wires, shock waves are emitted from the electrode pair. Placing the wire in the slot enables placing the non-insulated distal end of the wire closely proximate to the distal end of the conductive sheath which promotes forward-biasing of the shock waves emitted from the electrode pair. Moreover, placing the wire in the slot also reduces the crossing profile of the emitter in comparison to a design wherein the wire is located on an inside surface of the conductive sheath. Thus, the slotted emitter configuration enables the catheter to navigate more severely occluded vessels by focusing the shock waves in a forward direction to break up occlusion forward of the device and reducing the profile of the device such that the catheter can navigate smaller channels.
The disclosure provides a catheter for treating occlusions in a body lumen, such as within blood vessels. The catheter can include an elongate tube with a member sealed to a distal end of the elongate tube that is fillable with a conductive fluid. The member can surround a cylindrical conductive sheath (e.g., an “emitter sheath”) that is circumferentially mounted around the elongate tube. The conductive sheath has at least one slot extending along a length of the conductive sheath. An insulated wire having a non-insulated distal end is positioned in the slot such that both an insulated portion and the non-insulated portion of the wire is disposed in the slot. The non-insulated distal end of the wire is spaced apart from the conductive sheath by a gap. When a voltage pulse is supplied to the insulated wire, such as via a pulsed voltage source, current flows across the gap to generate cavitation bubbles and/or shock waves. The cavitation bubbles and/or shock waves break apart occlusions in the body lumen.
The slots of the conductive sheath enable placement of the non-insulated portion of the insulated wire proximate to the distal end of the conductive sheath, which promotes forward-biased cavitation bubbles and/or shock waves. Forward biased or distally directed (these terms are used interchangeably herein) cavitation bubbles and/or shock waves enables the catheter of the invention to be advanced farther within tight occlusions (or CTOs after creating a channel). The slots of the conductive sheath also provide a recessed location for the placement of the insulated wires, which reduces the overall diameter of the distal end of the catheter relative to a catheter that includes a cylindrical sheath that surrounds insulated wires. The elongate tube can also include grooves for placement of the insulated wires that provide a recessed location for the length of the wire that extends from a proximal side of the catheter (e.g., outside a patient) to the emitter near a distal end of the catheter (e.g., proximate to a treatment location). Placing the wires in grooves of the elongate tube similarly reduces the overall diameter of the catheter relative to a design that does not include grooves, which further improves the ability of the catheter according to the invention to treat tight occlusions and/or CTOs.
According to an aspect, a catheter for treating an occlusion in a body lumen includes an elongate tube; a member sealed to a distal end of the elongate tube that is fillable with a conductive fluid; a cylindrical conductive sheath circumferentially mounted around the elongate tube within the member, the conductive sheath comprising a slot extending along a length of the conductive sheath; and a wire at least partially disposed in the slot, wherein a distal end of the wire is spaced apart from the conductive sheath by a gap in an arrangement such that when a voltage pulse is supplied to the insulated wire current flows across the gap to generate cavitation bubbles and/or shock waves.
A majority of the at least a portion of the wire that is in the slot may be insulated. The catheter may include a second wire that is connected to the conductive sheath. The second wire may be connected to a proximal end of the conductive sheath.
The slot may terminate with a cutout, and the non-insulated distal end of the insulated wire may be positioned in the cutout. The cutout may be spaced apart from a distal end of the conductive sheath. The cutout may have a circular shape.
The conductive sheath may include a longitudinal axis and at least a portion of the slot may extend circumferentially around the conductive sheath with respect to the longitudinal axis. The slot may include a helical shape. The slot may extend along the entire length of the conductive sheath.
The slot may be a first slot and the insulated wire may be a first insulated wire, and the catheter may include a second slot extending along the length of the conductive sheath; and a second insulated wire having an insulated portion and a non-insulated distal end, where the insulated portion and the non-insulated distal end are disposed in the second slot; wherein the non-insulated distal end is spaced apart from the conductive sheath by a gap in an arrangement such that when the voltage pulse is supplied to the first insulated wire and the second insulated wire, current flows across the gap between the non-insulated distal end of the first insulated wire and the conductive sheath and across the gap between the non-insulated distal end of the second insulated wire and the conductive sheath to generate cavitation bubbles and/or shock waves at each gap.
The elongate tube may include at least one groove extending along a length of the elongate tube, and wherein the insulated wire extends along the at least one groove of the elongate tube. The insulated wire may include an insulating layer wrapping around a length of the insulated wire, wherein the distal end of the insulated wire is exposed from the insulating layer to form the non-insulated distal end.
The insulated wire may include an insulating layer wrapping around the insulated wire, and wherein a strip of the insulating layer is removed to form the non-insulated distal end. The at least a portion of the insulated wire may be flattened. The elongate tube may include a guidewire lumen for receiving a guidewire, wherein the catheter is configured to be advanced into the body lumen over the guidewire. The elongate tube may include one or more flush lumens for removing the cavitation bubbles and/or shock waves from within the member.
According to an aspect, a system for treating an occlusion in a body lumen includes a catheter that includes an elongate tube; a member sealed to a distal end of the elongate tube that is fillable with a conductive fluid; a cylindrical conductive sheath circumferentially mounted around the elongate tube within the member, the conductive sheath comprising a first slot and a second slot extending along a length of the conductive sheath; a first insulated wire having an insulated portion and a non-insulated distal end, both the insulated portion and the non-insulated distal end being disposed in the first slot wherein the non-insulated distal end is and spaced apart from the conductive sheath by a gap; a second insulated wire having an insulated portion and a non-insulated distal end, both the insulated portion and the non-insulated distal end being disposed in the second slot, wherein the non-insulated distal end is and spaced apart from the conductive sheath by a gap; and a power source that supplies the first insulated wire and the second insulated wire with a voltage pulse causing current to flow across the gap between the non-insulated distal end of the first insulated wire and the conductive sheath and the gap between the non-insulated distal end of the second insulated wire and the conductive sheath to generate cavitation bubbles and/or shock waves at each gap.
A majority of a length of the first slot may include the insulated portion of the first insulated wire and a majority of a length of the second slot may include the insulated portion of the second insulated wire. The first slot may terminate with a cutout that is spaced apart from a distal end of the conductive sheath, and the non-insulated distal end of the first insulated wire may be positioned in the cutout and the second slot extends along the entire length of the conductive sheath.
The first slot and the second slot each may terminate with a cutout that is spaced apart from a distal end of the conductive sheath, wherein the non-insulated distal end of the first insulated wire is positioned in the cutout of the first slot and the non-insulated distal end of the second insulated wire is positioned in the cutout of the second slot. The cutout of each of first slot and the second slot may have a circular shape.
The conductive sheath may include a longitudinal axis and at least a portion of the slot may extend circumferentially around the conductive sheath with respect to the longitudinal axis. The slot may have a helical shape.
Illustrative aspects of the present disclosure are described in detail below with reference to the following figures. It is intended that the embodiments and figures disclosed herein are to be considered illustrative and exemplary rather than restrictive.
The following description is presented to enable a person of ordinary skill in the art to make and use the various embodiments and aspects thereof disclosed herein. Descriptions of specific devices, assemblies, techniques, and applications are provided only as examples. Various modifications to the examples described herein will be readily apparent to those of ordinary skill in the art, and the general principles described herein may be applied to other examples and applications without departing from the spirit and scope of the various embodiments and aspects thereof. Thus, the various embodiments and aspects thereof are not intended to be limited to the examples described herein and shown but are to be accorded the scope consistent with the claims.
As used herein, the term “electrode” refers to an electrically conducting element (typically made of metal) that receives electrical current and subsequently releases the electrical current to another electrically conducting element. In the context of the present disclosure, electrodes are often positioned relative to each other, such as in an arrangement of an inner electrode and an outer electrode. Accordingly, as used herein, the term “electrode pair” refers to two electrodes that are positioned adjacent to each other such that application of a sufficiently high voltage to the electrode pair will cause an electrical current to transmit across the gap (also referred to as a “spark gap”) between the two electrodes (e.g., from an inner electrode to an outer electrode, or vice versa, optionally with the electricity passing through a conductive fluid or gas therebetween). In some contexts, one or more electrode pairs may also be referred to as an electrode assembly. In the context of the present disclosure, the term “emitter” broadly refers to the region of an electrode assembly where the current transmits across the electrode pair, generating a shock wave. The term “emitter sheath” refers to a sheath of conductive material that may form one or more electrodes of one or more electrode pairs, thereby forming a location of one or more emitters.
Described herein are catheters incorporating design elements that reduce the overall diameter of the catheter and promote forward-biased shock waves, which enables the catheter to treat tighter, hard-to-cross calcified lesions and chronic total occlusions. The present invention is similar to existing IVL systems in that it can comprise an array of lithotripsy emitters (e.g., electrode pairs) on a catheter that is inserted into a patient's vasculature to deliver shock waves to an occlusion. However, the present invention incorporates emitter sheaths with slots that provide a recessed location such that the insulated wires that deliver voltage to the emitter can be positioned within the slots and reduce the overall diameter of the catheter. Furthermore, placing the insulated wires within the slots also enables forward-biased shock waves by placing a non-insulated portion of the wires proximate to a distal end of the emitter, thereby improving the catheter's ability to break up occlusions located forward of or distal to the device (e.g., in front of the device). The forward-biased design and reduced profile catheter can thus generate channels through occluded vessels and navigate smaller channels in occluded vessels, thereby enabling the catheter to treat hard-to-cross calcified lesions. It should be appreciated that forward-biased shock waves are directed toward and/or past the distal end of the catheter devices described herein.
A flexible cap 18 (e.g., a low-profile flexible angioplasty balloon, a polymer membrane in tension that can flex outward, etc.) is sealably attached to the distal end 14 of the catheter 10, forming an annular channel around the shaft 12 of the catheter. The flexible cap 18 surrounds the shock wave generator 16, such that the shock waves are produced in a closed system within the flexible cap 18. The flexible cap 18 is filled with a conductive fluid, such as saline. The flexible cap 18 can alternatively be referred to as a “window”, in particular for implementations where when the interior volume is filled with a fluid and pressurized, the window maintains a substantively constant volume and profile. The conductive fluid allows the acoustic shock waves to propagate outwardly from the electrode pairs of the shock wave generator 16 through the walls of the flexible cap 18 and then into the target lesion. In one or more examples, the conductive fluid may also contain x-ray contrast fluid to permit fluoroscopic viewing of the catheter 10 during use. In some implementations, the material that forms the primary surface(s) of the flexible cap 18 through which shock waves pass can be a non-compliant polymer. In other implementations, a rigid and inflexible structure may be used in lieu of flexible cap 18.
The catheter 10 includes a proximal end 22 (or handle) that remains outside of a patient's vasculature during treatment. The proximal end 22 includes an entry port for receiving the guidewire 20. The proximal end 22 also includes a fluid port 26 for receiving a conductive fluid for filling and emptying the flexible cap during treatment. An electrical connection port 24 is also located on the proximal end 22 to provide an electrical connection between the distal shock wave generator 16 and an external pulsed high voltage source 28, such as the intravascular lithotripsy (IVL) generator shown in
The catheter 10 also includes a flexible shaft 12 that extends from the proximal end 22 to the distal end 14 of the catheter. The shaft 12 provides various internal conduits connecting elements of the distal end 14 with the proximal end 22 of the catheter (see, e.g.,
When treating a total occlusion as shown in
After inflating the flexible cap 18, a voltage pulse is applied by the voltage source 28 across the one or more electrode pairs (i.e., emitters of the shock wave generator 16). Each pulse initially ionizes the conductive fluid inside the flexible cap 18 to create small gas bubbles around the shock wave generator 16 that insulate the electrodes. Fluid can be continuously flowed into the flexible cap 18 and evacuated via a flush lumen at a constant rate to clear bubbles and debris from the electrodes. The fluid flow rate may be controlled throughout treatment, but is generally in the range of approximately one to three milliliters per minute (1-3 ml/min). Subsequently, a plasma arc forms across a gap between the electrodes of the electrode pairs, creating a low impedance path where current flows freely. The heat from the plasma arc heats the conductive fluid to create a rapidly expanding vapor bubble. The expansion and collapse of the vapor bubble creates a shock wave that propagates through the fluid in the flexible cap 18, through the walls of the flexible cap 18, and into the nearby occlusion where the energy breaks up the hardened lesion.
For treatment of an occlusion in a blood vessel, the voltage pulse applied by the voltage source 28 is typically in the range of from about two thousand to three thousand volts (2,000-3,000 V). In some implementations, the voltage pulse applied by the voltage source can be up to about ten thousand volts (10,000 V). The pulse width of the applied voltage pulses ranges between two microseconds and six microseconds (2-6 μs). The repetition rate or frequency of the applied voltage pulses may be between about 1 Hz and 10 Hz. The total number of pulses applied by the voltage source 28 may be, for example, sixty (60) pulses, eighty (80) pulses, one hundred twenty (120) pulses, three hundred (300) pulses, or up to five hundred (500) pulses, or other increments of pulses within this range. The preferred voltage, repetition rate, and number of pulses may vary depending on, e.g., the size of the lesion, the extent of calcification, the size of the blood vessel, the attributes of the patient, or the stage of treatment. For instance, a physician may start with low energy shock waves and increase the energy as needed during the procedure, or vice versa. The magnitude of the shock waves can be controlled by controlling the voltage, current, duration, and repetition rate of the pulsed voltage form the voltage source 28. More information about the physics of shock wave generation and their control can be found in U.S. Pat. Nos. 8,956,371; 8,728,091; 9,522,012; and 10,226,265, each of which is incorporated by reference.
The progress of the procedure may be monitored by x-ray and/or fluoroscopy. As the lesion is broken up or loosened by the shock waves, the guidewire and catheter can be advanced farther into the lesion, and the shock wave treatment can be repeated until the total occlusion is cleared or until the diameter of the vessel permits the placement of a second treatment device having a larger profile. For example, the enlarged channel can receive a different catheter having a more conventional angioplasty balloon or differently oriented shock wave sources. Catheters of this type are described in U.S. Pat. No. 8,747,416 and U.S. Publication No. 2019/0150960, cited above. Once the lesion has been sufficiently treated, the catheter 10 and the guidewire 20 can be withdrawn from the patient.
In variations in which the slotted emitter sheath serves as an electrode of an electrode pair in an emitter, the other electrode of the pair can include a wire that is positioned within the slot, as will be discussed further below. When voltage is supplied to a wire and across an electrode pair and shock waves are generated, however, the most distal portion of the wire can erode (e.g., retreat from the distal end of the wire towards the proximal end of the wire). As the wire erodes and the furthest distal portion recedes, the origin point from which shock waves are generated may also recede. Accordingly, it may be beneficial for the slot of an emitter to include at least a portion that extends circumferentially around the emitter sheath, rather than only along a longitudinal axis of the emitter sheath.
Another design which similarly encourages forward biased shock waves for a longer period is shown in
The emitter sheath 300 is a generally cylindrical sheath. The emitter sheath 300 may be formed from a variety of lightweight conductive materials, including metals and alloys such as stainless steel, cobalt chromium, platinum chromium, cobalt chromium platinum palladium iridium, or platinum iridium, or a mixture of such materials. In one or more examples, a catheter may include a plurality of slotted emitters positioned at various locations along a length of the catheter (e.g., longitudinally spaced apart from one another), and may include a combination of slotted emitters with any variation of slots, such as the slots with circular cutouts as shown with respect to the slotted emitter sheath 300, through cut slots as shown with respect to the slotted emitter sheath 310, slots with rounded ends as shown with respect to the slotted emitter sheath 320, helical slots as shown with respect to the slotted emitter sheath 330, and/or contorted slots as shown with respect to the slotted emitter sheath 340.
Each of the lead wire 410 and the return wire 412 can be insulated wires with insulation 409 extending along the length of the wire (e.g., from a proximal connection to a voltage source to a distal position as part of an electrode assembly). The wires may be cylindrical wires (as shown in
At least a portion of the lead wire 410 is exposed to form an electrode of an electrode pair opposite a section of electrode sheath 406 of the emitter 400. Similarly, at least a portion of the return wire 412 is exposed to form an electrode of an electrode pair opposite a section of electrode sheath 406 of the emitter 400. The exposed portion (e.g., the non-insulated or insulated removed portion) of each wire can be an area of the wire wherein the insulating layer that surrounds the insulated wire is exposed, or wherein a strip of the insulating layer is removed. The insulation-removed portion may include just the distal faces 411 and 413 of the lead wire 410 and return wire 412. Optionally, the non-insulated portion of the wires can include a larger portion of the wire than just the distal face or distal end. For instance, the distal tip, including a portion of the shaft of the wire and the distal face, may form the non-insulated portion of the wire (as depicted in
The emitter 400 includes two electrode pairs, a first pair including the distal face 411 of the lead wire 410 and a first circular cutout 404 of the emitter sheath 406 (more particularly, a surface of the circular cutout that is proximate to the distal face 411), and a second pair including the distal face 413 of the return wire 412 and a second circular cutout 404 of the emitter sheath 406. Where the emitter instead includes a slot that extends along the entire length of the emitter (e.g., slot 306 of
The distal faces 411 and 413 of the lead wire 410 and return wire 412 are each separated from an inner surface of the circular cutout 404 of the emitter sheath 406 by a gap. When voltage is applied across the lead wire 410 and the return wire 412, current flows across the gaps to generate shock waves. For instance, current may flow from the distal face 411 of the lead wire 410 to the emitter sheath 406 by jumping across the gap between the distal face 411 and the inner face of the cutout 404 and then travel from the emitter sheath 406 to the return wire 412 by jumping across the gap between the inner face of the cutout 404 to the distal face 413 of the return wire 412.
The lead wire 410 receives voltage from a voltage source (such as voltage source 28 of
By locating the lead wire 410 and return wire 412 in the slots 402 such that the insulation-removed portions (e.g., the distal faces 411 and 413) are located proximate to a distal end of the emitter sheath 406, the emitter 400 promotes forward-biased and/or distally directed shock waves that are generated when current jumps across the gaps between the electrodes of each respective electrode pair. That is, shock waves generated when current jumps, for example, from the distal face 411 of the lead wire 410 to the emitter sheath 406, will propagate in a forward direction (e.g., to the right based on the orientation shown in
In addition to promoting forward-biased shock waves, locating the lead wire 410 and return wire 412 in the slots 402 of the emitter sheath 406 also reduces the overall diameter of the emitter 400 relative to a configuration wherein the wires are located within the emitter sheath 406 (e.g., in the interior of the emitter sheath 406). Reducing the overall diameter of the emitter 400 improves the navigability of the catheter within tight occlusions, as it enables the catheter to be advanced within smaller spaces than a catheter with a larger overall diameter.
Another design configuration that reduces the overall diameter of the catheter is incorporating grooves in the elongate tube that receive the wires of the emitter 400.
As shown in
The placement and spacing of the electrode pairs can be controlled to provide a more effective shock wave treatment. For instance, the electrode pairs of a shock wave generator may be spaced circumferentially around the distal end of the catheter in consistent increments, e.g., 180 degrees apart or 90 degrees apart, to generate shock waves evenly around the catheter. The electrode pairs of the emitter 400 of
As compared to the catheter 602, the catheter 620 includes wires 613 located in grooves of the elongate tube (such as grooves 415 of elongate tube 420
Additionally, by positioning the distal end of the wires 613 proximate to the distal end of the emitter sheath 606, the origin of the shock waves generated via the emitter 621 (from the current jumping between the wires and the emitter sheath) is proximate to the distal end of the emitter sheath 606. Placing the origin of the shock waves proximate to the distal end of the emitter sheath 606 enables the catheter 620 to generate shock waves that are forward-biased and with the most distal portion of those shock waves applying spherical pressure against occlusions that are in front of the catheter 620. In contrast, the origin of the shock waves generated by the catheter 602 is not as proximate to the distal end of the emitter. Accordingly, less (or none) of the spherical pressure of the shock waves generated by the catheter 602 does not impinge against the occlusions that are in front of the catheter 620 and instead dissipates as it propagates generally outwardly. Accordingly, as compared to the catheter 602, the catheter 620 generates forward-biased shock waves and harnesses the distal spherical pressure of these waves to break up occlusions in front of the catheter 620 thus enabling the catheter 620 to be advanced farther within tight occlusions.
In one or more examples, a catheter comprising a slotted emitter sheath, such as the catheter 620, can include of one or more coatings and/or liners that can reduce (or prevent) friction and/or drag when using the catheter. Friction and/or drag may be generated, for example, between the outer surface of a catheter and the vessel and/or between an internal guidewire lumen of the catheter and a guidewire as the catheter is inserted into a body lumen. To reduce friction and/or drag, a catheter can include a coating and/or liner at one or both of these interfaces. For example, the catheter can include a coating and/or liner on a portion or the entirety of an inner surface of a guidewire lumen that receives a guidewire. For instance, the catheter 620 can include a coating and/or liner on the inner surface of the guidewire lumen 611 to prevent or reduce friction and/or drag between the guidewire lumen 611 and a guidewire as the catheter 620 travels along a guidewire positioned in the guidewire lumen 611. In addition or alternatively, a catheter can include an external coating and/or a liner on the external surface of the catheter. For example, the catheter 620 could include a coating and/or liner on the outer surface of the catheter 620 to prevent or reduce friction and/or drag between the catheter 620 and the body lumen the catheter 620 is traveling through.
By incorporating one or more liners and/or coatings that reduce or prevent friction and/or drag, the catheter can travel more easily within the body lumen, which can improve the device tracking and enable the catheter to reach and treat more distal lesions than a catheter without liners and/or coatings. Materials that a liner and/or coating may include that can reduce friction and/or drag include, for example, polymeric materials such as polytetrafluoroethylene (PTFE) and high density polyethylene (HDPE), hydrophilic or hydrophobic coatings, etc.
Exemplary uses of IVL devices as described herein can follow a therapeutic procedure as follows. Identification of a target lesion (e.g., a CTO) within patient vasculature (e.g., coronary, peripheral, etc.) is done with real-time or prior-to-procedure imaging or sensing. An IVL catheter having a forward-biased shock wave generator is introduced into the patient vasculature and deployed at one end of the target lesion site. The IVL catheter is then operated to have electrical current delivered to the electrodes and across the spark gaps of the electrode pairs to thereby generate shock waves. Due to the structure of the emitter(s), the shock waves are biased in a relatively forward direction, toward and/or past the distal end of the catheter. The shock waves subsequently encounter and disrupt (break up, crack, etc.) the target lesion. The disruption of the target lesion can allow for advancement of the IVL catheter into or further within the target lesion, where additional cycles of shock wave generation can be executed, thereby further disrupting the target lesion. After the target lesion has been sufficiently disrupted following one or more cycles and or one or more advancements through the lesion, the IVL catheter can be withdrawn from the target region of the patient vasculature.
Although the electrode assemblies and catheter devices described herein have been discussed primarily in the context of treating coronary occlusions, such as lesions in vasculature, the electrode assemblies and catheters herein can be used for a variety of occlusions, such as occlusions in the peripheral vasculature (e.g., above-the-knee, below-the-knee, iliac, carotid, etc.). For further examples, similar designs may be used for treating soft tissues, such as cancer and tumors (i.e., non-thermal ablation methods), blood clots, fibroids, cysts, organs, scar and fibrotic tissue removal, or other tissue destruction and removal. Electrode assembly and catheter designs could also be used for neurostimulation treatments, targeted drug delivery, treatments of tumors in body lumens (e.g., tumors in blood vessels, the esophagus, intestines, stomach, or vagina), wound treatment, non-surgical removal and destruction of tissue, or used in place of thermal treatments or cauterization for venous insufficiency and fallopian ligation (i.e., for permanent female contraception).
In one or more examples, the electrode assemblies and catheters described herein could also be used for tissue engineering methods, for instance, for mechanical tissue decellularization to create a bioactive scaffold in which new cells (e.g., exogenous or endogenous cells) can replace the old cells; introducing porosity to a site to improve cellular retention, cellular infiltration/migration, and diffusion of nutrients and signaling molecules to promote angiogenesis, cellular proliferation, and tissue regeneration similar to cell replacement therapy. Such tissue engineering methods may be useful for treating ischemic heart disease, fibrotic liver, fibrotic bowel, and traumatic spinal cord injury (SCI). For instance, for the treatment of spinal cord injury, the devices and assemblies described herein could facilitate the removal of scarred spinal cord tissue, which acts like a barrier for neuronal reconnection, before the injection of an anti-inflammatory hydrogel loaded with lentivirus to genetically engineer the spinal cord neurons to regenerate.
The elements and features of the exemplary electrode assemblies and catheters discussed above may be rearranged, recombined, and modified, without departing from the present invention. Furthermore, numerical designators such as “first”, “second”, “third”, “fourth”, etc. are merely descriptive and do not indicate a relative order, location, or identity of elements or features described by the designators. For instance, a “first” shock wave may be immediately succeeded by a “third” shock wave, which is then succeeded by a “second” shock wave. As another example, a “third” emitter may be used to generate a “first” shock wave and vice versa. Accordingly, numerical designators of various elements and features are not intended to limit the disclosure and may be modified and interchanged without departing from the subject invention.
It should be understood that the foregoing is only illustrative of the principles of the invention, and that various modifications, alterations and combinations can be made by those skilled in the art without departing from the scope and spirit of the invention. Any of the variations of the various catheters disclosed herein can include features described by any other catheters or combination of catheters herein. Furthermore, any of the methods can be used with any of the catheters disclosed. Accordingly, it is not intended that the invention be limited, except as by the appended claims.
Number | Name | Date | Kind |
---|---|---|---|
2916647 | George | Dec 1959 | A |
3412288 | Ostrander | Nov 1968 | A |
3413976 | Roze | Dec 1968 | A |
3524101 | Barbini | Aug 1970 | A |
3583766 | Padberg | Jun 1971 | A |
3785382 | Schmidt-Kloiber et al. | Jan 1974 | A |
3902499 | Shene | Sep 1975 | A |
3942531 | Hoff et al. | Mar 1976 | A |
4027674 | Tessler et al. | Jun 1977 | A |
4030505 | Tessler | Jun 1977 | A |
4445509 | Auth | May 1984 | A |
4662126 | Malcolm | May 1987 | A |
4662375 | Hepp et al. | May 1987 | A |
4671254 | Fair | Jun 1987 | A |
4685458 | Leckrone | Aug 1987 | A |
4741405 | Moeny et al. | May 1988 | A |
4809682 | Forssmann et al. | Mar 1989 | A |
4813934 | Engelson et al. | Mar 1989 | A |
4878495 | Grayzel | Nov 1989 | A |
4890603 | Filler | Jan 1990 | A |
4900303 | Lemelson | Feb 1990 | A |
4990134 | Auth | Feb 1991 | A |
4994032 | Sugiyama et al. | Feb 1991 | A |
5009232 | Hassler et al. | Apr 1991 | A |
5046503 | Schneiderman | Sep 1991 | A |
5057103 | Davis | Oct 1991 | A |
5057106 | Kasevich et al. | Oct 1991 | A |
5061240 | Cherian | Oct 1991 | A |
5078717 | Parins et al. | Jan 1992 | A |
5102402 | Dror et al. | Apr 1992 | A |
5103804 | Abele et al. | Apr 1992 | A |
5116227 | Levy | May 1992 | A |
5152767 | Sypal et al. | Oct 1992 | A |
5152768 | Bhatta | Oct 1992 | A |
5154722 | Filip et al. | Oct 1992 | A |
5176675 | Watson et al. | Jan 1993 | A |
5195508 | Muller et al. | Mar 1993 | A |
5245988 | Einars et al. | Sep 1993 | A |
5246447 | Rosen et al. | Sep 1993 | A |
5254121 | Manevitz et al. | Oct 1993 | A |
5281231 | Rosen et al. | Jan 1994 | A |
5295958 | Shturman | Mar 1994 | A |
5304134 | Kraus et al. | Apr 1994 | A |
5321715 | Trost | Jun 1994 | A |
5324255 | Passafaro et al. | Jun 1994 | A |
5336234 | Vigil et al. | Aug 1994 | A |
5362309 | Carter | Nov 1994 | A |
5364393 | Auth et al. | Nov 1994 | A |
5368591 | Lennox et al. | Nov 1994 | A |
5395335 | Jang | Mar 1995 | A |
5417208 | Winkler | May 1995 | A |
5425735 | Rosen et al. | Jun 1995 | A |
5454809 | Janssen | Oct 1995 | A |
5472406 | de la Torre et al. | Dec 1995 | A |
5505702 | Arney | Apr 1996 | A |
5582578 | Zhong et al. | Dec 1996 | A |
5584843 | Wulfman et al. | Dec 1996 | A |
5603731 | Whitney | Feb 1997 | A |
5609606 | O'Boyle | Mar 1997 | A |
5662590 | de la Torre et al. | Sep 1997 | A |
5697281 | Eggers et al. | Dec 1997 | A |
5709676 | Alt | Jan 1998 | A |
5735811 | Brisken | Apr 1998 | A |
5846218 | Brisken et al. | Dec 1998 | A |
5891089 | Katz et al. | Apr 1999 | A |
5893840 | Hull et al. | Apr 1999 | A |
5931805 | Brisken | Aug 1999 | A |
6007530 | Dornhofer et al. | Dec 1999 | A |
6033371 | Torre et al. | Mar 2000 | A |
6056722 | Jayaraman | May 2000 | A |
6080119 | Schwarze et al. | Jun 2000 | A |
6083232 | Cox | Jul 2000 | A |
6090104 | Webster et al. | Jul 2000 | A |
6113560 | Simnacher | Sep 2000 | A |
6132444 | Shturman et al. | Oct 2000 | A |
6146358 | Rowe | Nov 2000 | A |
6186963 | Schwarze et al. | Feb 2001 | B1 |
6210404 | Shadduck | Apr 2001 | B1 |
6210408 | Chandrasekaran et al. | Apr 2001 | B1 |
6215734 | Moeny et al. | Apr 2001 | B1 |
6217531 | Reitmajer | Apr 2001 | B1 |
6267747 | Samson et al. | Jul 2001 | B1 |
6277138 | Levinson et al. | Aug 2001 | B1 |
6287272 | Brisken et al. | Sep 2001 | B1 |
6352535 | Lewis et al. | Mar 2002 | B1 |
6364894 | Healy et al. | Apr 2002 | B1 |
6367203 | Graham et al. | Apr 2002 | B1 |
6371971 | Tsugita et al. | Apr 2002 | B1 |
6398792 | O'Connor | Jun 2002 | B1 |
6406486 | de la Torre et al. | Jun 2002 | B1 |
6440061 | Wenner et al. | Aug 2002 | B1 |
6440124 | Esch et al. | Aug 2002 | B1 |
6494890 | Shturman et al. | Dec 2002 | B1 |
6514203 | Bukshpan | Feb 2003 | B2 |
6524251 | Rabiner et al. | Feb 2003 | B2 |
6589253 | Cornish et al. | Jul 2003 | B1 |
6607003 | Wilson | Aug 2003 | B1 |
6638246 | Naimark et al. | Oct 2003 | B1 |
6652547 | Rabiner et al. | Nov 2003 | B2 |
6666834 | Restle et al. | Dec 2003 | B2 |
6689089 | Tiedtke et al. | Feb 2004 | B1 |
6736784 | Menne et al. | May 2004 | B1 |
6740081 | Hilal | May 2004 | B2 |
6755821 | Fry | Jun 2004 | B1 |
6939320 | Lennox | Sep 2005 | B2 |
6989009 | Lafontaine | Jan 2006 | B2 |
7066904 | Rosenthal et al. | Jun 2006 | B2 |
7087061 | Chernenko et al. | Aug 2006 | B2 |
7241295 | Maguire | Jul 2007 | B2 |
7267654 | Matula | Sep 2007 | B2 |
7309324 | Hayes et al. | Dec 2007 | B2 |
7389148 | Morgan | Jun 2008 | B1 |
7505812 | Eggers et al. | Mar 2009 | B1 |
7569032 | Naimark et al. | Aug 2009 | B2 |
7618432 | Pedersen et al. | Nov 2009 | B2 |
7850685 | Kunis et al. | Dec 2010 | B2 |
7853332 | Olsen et al. | Dec 2010 | B2 |
7873404 | Patton | Jan 2011 | B1 |
7951111 | Drasler et al. | May 2011 | B2 |
8162859 | Schultheiss et al. | Apr 2012 | B2 |
8177801 | Kallok et al. | May 2012 | B2 |
8353923 | Shturman | Jan 2013 | B2 |
8556813 | Cioanta et al. | Oct 2013 | B2 |
8574247 | Adams et al. | Nov 2013 | B2 |
8709075 | Adams et al. | Apr 2014 | B2 |
8728091 | Hakala et al. | May 2014 | B2 |
8747416 | Hakala et al. | Jun 2014 | B2 |
8888788 | Hakala et al. | Nov 2014 | B2 |
8956371 | Hawkins et al. | Feb 2015 | B2 |
8956374 | Hawkins et al. | Feb 2015 | B2 |
9005216 | Hakala et al. | Apr 2015 | B2 |
9011462 | Adams et al. | Apr 2015 | B2 |
9011463 | Adams et al. | Apr 2015 | B2 |
9044618 | Hawkins et al. | Jun 2015 | B2 |
9044619 | Hawkins | Jun 2015 | B2 |
9072534 | Adams et al. | Jul 2015 | B2 |
9138249 | Adams et al. | Sep 2015 | B2 |
9198825 | Katragadda et al. | Dec 2015 | B2 |
9333000 | Hakala et al. | May 2016 | B2 |
9421025 | Hawkins et al. | Aug 2016 | B2 |
9433428 | Hakala et al. | Sep 2016 | B2 |
9522012 | Adams | Dec 2016 | B2 |
9642673 | Adams et al. | May 2017 | B2 |
9993292 | Adams et al. | Jun 2018 | B2 |
10039561 | Adams et al. | Aug 2018 | B2 |
10118015 | De La Rama et al. | Nov 2018 | B2 |
10149690 | Hawkins et al. | Dec 2018 | B2 |
10154799 | Van Der Weide et al. | Dec 2018 | B2 |
10159505 | Hakala et al. | Dec 2018 | B2 |
10206698 | Hakala et al. | Feb 2019 | B2 |
10226265 | Ku et al. | Mar 2019 | B2 |
10517620 | Adams | Dec 2019 | B2 |
10517621 | Adams | Dec 2019 | B1 |
10555744 | Nguyen | Feb 2020 | B2 |
10682178 | Adams et al. | Jun 2020 | B2 |
10702293 | Adams et al. | Jul 2020 | B2 |
10709462 | Nguyen | Jul 2020 | B2 |
10959743 | Adams et al. | Mar 2021 | B2 |
10966737 | Nguyen | Apr 2021 | B2 |
10973538 | Hakala et al. | Apr 2021 | B2 |
11000299 | Hawkins et al. | May 2021 | B2 |
11076874 | Hakala et al. | Aug 2021 | B2 |
11337713 | Nguyen et al. | May 2022 | B2 |
11432834 | Hakala et al. | Sep 2022 | B2 |
11534187 | Bonutti | Dec 2022 | B2 |
11596424 | Hakala et al. | Mar 2023 | B2 |
11622780 | Nguyen et al. | Apr 2023 | B2 |
11696799 | Adams et al. | Jul 2023 | B2 |
20010044596 | Jaafar | Nov 2001 | A1 |
20020045890 | Celliers et al. | Apr 2002 | A1 |
20020082553 | Duchamp | Jun 2002 | A1 |
20020177889 | Brisken et al. | Nov 2002 | A1 |
20030004434 | Greco et al. | Jan 2003 | A1 |
20030163081 | Constantz et al. | Aug 2003 | A1 |
20030176873 | Chernenko et al. | Sep 2003 | A1 |
20030229370 | Miller | Dec 2003 | A1 |
20040006333 | Arnold et al. | Jan 2004 | A1 |
20040010249 | Truckai et al. | Jan 2004 | A1 |
20040044308 | Naimark et al. | Mar 2004 | A1 |
20040082859 | Schaer | Apr 2004 | A1 |
20040097963 | Seddon | May 2004 | A1 |
20040097996 | Rabiner et al. | May 2004 | A1 |
20040162508 | Uebelacker | Aug 2004 | A1 |
20040249401 | Rabiner et al. | Dec 2004 | A1 |
20040254570 | Hadjicostis et al. | Dec 2004 | A1 |
20050015953 | Keidar | Jan 2005 | A1 |
20050021013 | Visuri et al. | Jan 2005 | A1 |
20050059965 | Eberl et al. | Mar 2005 | A1 |
20050075662 | Pedersen et al. | Apr 2005 | A1 |
20050090846 | Pedersen et al. | Apr 2005 | A1 |
20050090888 | Hines et al. | Apr 2005 | A1 |
20050113722 | Schultheiss | May 2005 | A1 |
20050113822 | Fuimaono et al. | May 2005 | A1 |
20050171527 | Bhola | Aug 2005 | A1 |
20050228372 | Truckai et al. | Oct 2005 | A1 |
20050245866 | Azizi | Nov 2005 | A1 |
20050251131 | Lesh | Nov 2005 | A1 |
20060004286 | Chang et al. | Jan 2006 | A1 |
20060069385 | Lafontaine et al. | Mar 2006 | A1 |
20060069424 | Acosta et al. | Mar 2006 | A1 |
20060074484 | Huber | Apr 2006 | A1 |
20060184076 | Gill et al. | Aug 2006 | A1 |
20060190022 | Beyar et al. | Aug 2006 | A1 |
20060221528 | Li et al. | Oct 2006 | A1 |
20070016112 | Schultheiss et al. | Jan 2007 | A1 |
20070088380 | Hirszowicz et al. | Apr 2007 | A1 |
20070129667 | Tiedtke et al. | Jun 2007 | A1 |
20070156129 | Kovalcheck | Jul 2007 | A1 |
20070239082 | Schultheiss et al. | Oct 2007 | A1 |
20070239253 | Jagger et al. | Oct 2007 | A1 |
20070244423 | Zumeris et al. | Oct 2007 | A1 |
20070250052 | Wham | Oct 2007 | A1 |
20070255270 | Carney | Nov 2007 | A1 |
20070282301 | Segalescu et al. | Dec 2007 | A1 |
20070299481 | Syed et al. | Dec 2007 | A1 |
20080077165 | Murphy | Mar 2008 | A1 |
20080097251 | Babaev | Apr 2008 | A1 |
20080188913 | Stone et al. | Aug 2008 | A1 |
20090030503 | Ho | Jan 2009 | A1 |
20090041833 | Bettinger et al. | Feb 2009 | A1 |
20090227992 | Nir et al. | Sep 2009 | A1 |
20090230822 | Kushculey et al. | Sep 2009 | A1 |
20090247945 | Levit et al. | Oct 2009 | A1 |
20090254114 | Hirszowicz et al. | Oct 2009 | A1 |
20090299447 | Jensen et al. | Dec 2009 | A1 |
20100016862 | Hawkins et al. | Jan 2010 | A1 |
20100036294 | Mantell et al. | Feb 2010 | A1 |
20100094209 | Drasler et al. | Apr 2010 | A1 |
20100114020 | Hawkins et al. | May 2010 | A1 |
20100114065 | Hawkins et al. | May 2010 | A1 |
20100121322 | Swanson | May 2010 | A1 |
20100179424 | Warnking et al. | Jul 2010 | A1 |
20100286709 | Diamant et al. | Nov 2010 | A1 |
20100305565 | Truckai et al. | Dec 2010 | A1 |
20100324554 | Gifford et al. | Dec 2010 | A1 |
20110034832 | Cioanta | Feb 2011 | A1 |
20110118634 | Golan | May 2011 | A1 |
20110208185 | Diamant et al. | Aug 2011 | A1 |
20110257523 | Hastings et al. | Oct 2011 | A1 |
20110295227 | Hawkins et al. | Dec 2011 | A1 |
20120071889 | Mantell et al. | Mar 2012 | A1 |
20120095461 | Herscher et al. | Apr 2012 | A1 |
20120116289 | Hawkins et al. | May 2012 | A1 |
20120143177 | Avitall | Jun 2012 | A1 |
20120157991 | Christian | Jun 2012 | A1 |
20120203255 | Hawkins et al. | Aug 2012 | A1 |
20120221013 | Hawkins et al. | Aug 2012 | A1 |
20120253358 | Golan | Oct 2012 | A1 |
20130030431 | Adams | Jan 2013 | A1 |
20130041355 | Heeren et al. | Feb 2013 | A1 |
20130116714 | Adams et al. | May 2013 | A1 |
20130123694 | Subramaniyan et al. | May 2013 | A1 |
20130150874 | Kassab | Jun 2013 | A1 |
20130253622 | Hooven | Sep 2013 | A1 |
20140039514 | Adams et al. | Feb 2014 | A1 |
20140046229 | Hawkins et al. | Feb 2014 | A1 |
20140046353 | Adams | Feb 2014 | A1 |
20140163592 | Hawkins et al. | Jun 2014 | A1 |
20140214061 | Adams et al. | Jul 2014 | A1 |
20150238209 | Hawkins et al. | Aug 2015 | A1 |
20150320432 | Adams | Nov 2015 | A1 |
20160135828 | Hawkins et al. | May 2016 | A1 |
20160151081 | Adams et al. | Jun 2016 | A1 |
20160184570 | Grace et al. | Jun 2016 | A1 |
20160324534 | Hawkins et al. | Nov 2016 | A1 |
20170135709 | Nguyen et al. | May 2017 | A1 |
20190388110 | Nguyen et al. | Dec 2019 | A1 |
20200085458 | Nguyen et al. | Mar 2020 | A1 |
20210085347 | Phan | Mar 2021 | A1 |
20210085383 | Vo et al. | Mar 2021 | A1 |
20210282792 | Adams et al. | Sep 2021 | A1 |
20210338258 | Hawkins et al. | Nov 2021 | A1 |
20220015785 | Hakala et al. | Jan 2022 | A1 |
20220183708 | Phan et al. | Jun 2022 | A1 |
20220240958 | Nguyen et al. | Aug 2022 | A1 |
20230043475 | Adams | Feb 2023 | A1 |
Number | Date | Country |
---|---|---|
2009313507 | Nov 2014 | AU |
2013284490 | May 2018 | AU |
2104414 | Feb 1995 | CA |
1204242 | Jan 1999 | CN |
1269708 | Oct 2000 | CN |
1942145 | Apr 2007 | CN |
101043914 | Sep 2007 | CN |
102057422 | May 2011 | CN |
102271748 | Dec 2011 | CN |
102355856 | Feb 2012 | CN |
102765785 | Nov 2012 | CN |
203564304 | Apr 2014 | CN |
3038445 | May 1982 | DE |
202006014285 | Dec 2006 | DE |
442199 | Aug 1991 | EP |
571306 | Nov 1993 | EP |
623360 | Nov 1994 | EP |
647435 | Apr 1995 | EP |
2253884 | Nov 2010 | EP |
2362798 | Apr 2014 | EP |
3434209 | Jan 2019 | EP |
S62-099210 | Jun 1987 | JP |
S62-275446 | Nov 1987 | JP |
H03-63059 | Mar 1991 | JP |
H06-125915 | May 1994 | JP |
H07-047135 | Feb 1995 | JP |
H08-89511 | Apr 1996 | JP |
H10-99444 | Apr 1998 | JP |
H10-314177 | Dec 1998 | JP |
H10-513379 | Dec 1998 | JP |
2002538932 | Nov 2002 | JP |
2004081374 | Mar 2004 | JP |
2004357792 | Dec 2004 | JP |
2008506447 | Dec 2004 | JP |
2011513694 | Dec 2004 | JP |
2011520248 | Dec 2004 | JP |
2005501597 | Jan 2005 | JP |
2005095410 | Apr 2005 | JP |
2005515825 | Jun 2005 | JP |
2006516465 | Jul 2006 | JP |
2007289707 | Nov 2007 | JP |
2007532182 | Nov 2007 | JP |
2011524203 | Sep 2011 | JP |
2011528963 | Dec 2011 | JP |
2012505050 | Mar 2012 | JP |
2012508042 | Apr 2012 | JP |
2015525657 | Sep 2015 | JP |
2015528327 | Sep 2015 | JP |
6029828 | Nov 2016 | JP |
6081510 | Feb 2017 | JP |
WO-1989011307 | Nov 1989 | WO |
WO-1996024297 | Aug 1996 | WO |
WO-1999000060 | Jan 1999 | WO |
WO-1999002096 | Jan 1999 | WO |
WO-2000056237 | Sep 2000 | WO |
WO-2004069072 | Aug 2004 | WO |
WO-2005099594 | Oct 2005 | WO |
WO-2005102199 | Nov 2005 | WO |
WO-2006006169 | Jan 2006 | WO |
WO-2006127158 | Nov 2006 | WO |
WO-2007088546 | Aug 2007 | WO |
WO-2007149905 | Dec 2007 | WO |
WO-2009121017 | Oct 2009 | WO |
WO-2009126544 | Oct 2009 | WO |
WO-2009136268 | Nov 2009 | WO |
WO-2009152352 | Dec 2009 | WO |
WO-2010014515 | Feb 2010 | WO |
WO-2010054048 | Sep 2010 | WO |
WO-2011006017 | Jan 2011 | WO |
WO-2011094111 | Aug 2011 | WO |
WO-2011143468 | Nov 2011 | WO |
WO-2012025833 | Mar 2012 | WO |
WO-2013059735 | Apr 2013 | WO |
WO-2014025397 | Feb 2014 | WO |
WO-2014025620 | Feb 2014 | WO |
WO-2015017499 | Feb 2015 | WO |
WO-2021061451 | Apr 2021 | WO |
Entry |
---|
International Search Report and Written Opinion received for International Application No. PCT/US2023/086441 mailed May 3, 2024, 9 pages. |